GI Oncology
Conference Coverage
SEER data show that pancreatic cancer mortality rates differ by ethnicity
SAN DIEGO – Between 2013 and 2015, mortality rates began to fall among all ethnicities, for reasons that remain unclear.
From the Journals
Pancreatic cancers often contained targetable mutations
A total of 17% of specimens harbored mutations that are potentially targetable with existing therapies. These mutations involved either RTK/ras/...
From the Journals
ctDNA predicts recurrence in nonmetastatic colorectal cancer
The sensitivity of ctDNA testing for disease recurrence was 100%, compared with 60% for CEA testing, in an observational study of 58 patients with...
From the Journals
AGA Clinical Practice Update: Direct-acting antivirals and hepatocellular carcinoma
For patients listed for liver transplantation, determine timing of DAA therapy on a case-by-case basis, consider regional wait times, availability...
From the Journals
Aspirin did not improve sensitivity of fecal immunochemical test
Detection of neoplasms on the fecal immunochemical test did not differ significantly between patients who took aspirin and those on a placebo.
Conference Coverage
Tenofovir disoproxil treated HBV with fewer future HCCs
VIENNA - Chronic hepatitis B virus-infected patients treated with tenofovir disoproxil fumarate developed significantly fewer hepatocellular...
From the Journals
No difference in GI cancer outcomes with vitamin D supplementation
The SUNSHINE and AMATERASU randomized clinical trials evaluated the use of vitamin D3 supplementation in patients with advanced or...
From the AGA Journals
MicroRNA-375 may be key to fibrolamellar carcinoma
Overexpression of microRNA-375 in a fibrolamellar carcinoma cell line suppressed cell migration and proliferation, which hints at therapeutic...
Conference Coverage
Preclinical findings highlight value of Lynch syndrome for cancer vaccine development
ATLANTA – Lynch syndrome is serving as a platform for the development of immunoprevention cancer vaccines.
From the Journals
Study eyes biomarkers of regorafenib response in hepatocellular carcinoma
Among 266 proteins tested, decreased levels of 5 correlated with significantly longer overall survival on regorafenib therapy.